EMA Releases Guideline on Covariates in Clinical Trials
Drugmakers planning to assign clinical trial participants to a separate arm of the study based on baseline monitoring must report those plans to the European Medicines Agency, including which factors — called covariates — they plan to rely on to make those assignments.
Often, these covariates are measures taken early in a trial, such as a baseline measurement, that would prompt sponsors to stratify patients into different treatment arms, according to guidance released last week.
- FDA Finalizes Guidance on Evaluating Drug Effects on Driving Ability December 18, 2017The FDA published guidance assisting sponsors in evaluating the effects of psychoactive drugs on the ability to operate a motor vehicle. The agency recommends a tiered approach to evaluating drug effects, consisting of pharmacology/toxicology, epidemiology and clinical behavioral assessments. Data obtained early in development can be used to guide the collection of subsequent data related […]
- EMA Adopts Guideline on Developing Treatments for Autism December 18, 2017The European Medicines Agency adopted a guideline for sponsors developing new products for autism spectrum disorder, providing recommendations on diagnostic criteria, target populations and clinical trial design.
- EMA Expands Safety Guidance for Developing Anticancer Drugs December 18, 2017The European Medicines Agency adopted the fifth revision of its substantive guideline covering all stages of oncology drug development, expanding upon the previous version’s section on safety data.
- Swissmedic updates Biosimilar Guidance and FAQs January 14, 2018Swissmedic has announced that as of now, the foreign comparator product with a biosimilar for the main studies can also originate from the USA, while that for supplementary studies can now also originate from Canada.mehr
- LOGFILE No. 01/2018 – Ask Our Experts – Part 2 – 4 GMP-Questions which might be of your interest January 9, 2018Ask Our Experts – Part 2 4 GMP-Questions which might be of your interest 7 minutes reading time by Sabine Rabus mehr
- India reports quality shortcomings of Chinese pharma companies January 8, 2018The Economic Times of India has published an article saying that the Indian government has issued showcause notices to eight Chinese pharmaceutical companies. Those companies were inspected by a special Indian inspection team and were found to supply poor quality APIs to drug manufacturers in India.mehr